VXRT News and Press, Vaxart Inc. From 06/06/23

SOUTH SAN FRANCISCO, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has commenced an underwritten public offering of its common stock. In addition, Vaxart expects to grant to the underwriter a 30-day option to purchase up to an additional 15% of shar...

No Vaccine Related Serious Adverse Events (SAEs) reported to date On track to report topline data from two Phase 2 norovirus vaccine studies over the next 3 months SOUTH SAN FRANCISCO, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that the l...

SOUTH SAN FRANCISCO, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it is launching an investor communication program that will give investors the ability to ask questions of Company management. The first event will be a fireside chat with Vaxart executives o...

2023-05-24 13:57:04 ET The Russell 3000 index will have a new look on June 26, after the market opens, when 286 securities will be added and 179 securities will be deleted as part of the annual reconstitution. Following are some notable healthcare companies which will be added an...

2023-05-24 13:33:04 ET In its preliminary annual 2023 Russell indexes reconstitution, a total of 164 companies will be added and 319 deleted from the Russell microcap index. Following notable healthcare companies will be added and deleted from Russell microcap index: Notable additio...

2023-05-15 13:13:19 ET Gainers: Ohmyhome Limited ( OMH ) +169% . NeoGames ( NGMS ) +112% . GSI Technology ( GSIT ) +36% . Vaxart ( VXRT ) +34% . WiSA Technologies ( WISA ) +35% . Scilex Holding Company ( SCLX ) +31% ....

2023-05-04 18:10:23 ET Vaxart, Inc. (VXRT) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Edward Berg - Senior Vice President and General Counsel Andrei Floroiu - Chief Executive Officer James Cummings - Chief Medical Officer Sea...

2023-05-04 16:27:27 ET Vaxart press release ( NASDAQ: VXRT ): Q1 GAAP EPS of -$0.19 in-line. Revenue of $0.67M (+644.4% Y/Y) misses by $0.13M . For further details see: Vaxart GAAP EPS of -$0.19 in-line, revenue of $0.67M misses by $0.13M

On track to report key top line data from two Phase 2 norovirus vaccine studies mid-year and in Q3 2023 Continue to anticipate cash runway into Q2 2024 Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:...

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the first quarter ended March 31, 2023 after the market close on Thurs...